Drug remdesivir, has been approved by the Taiwan health authorities as a treatment for coronavirus disease 2019 (COVID-19) as it showed promising result in early testing, said the Central Epidemic Command Center (CECC), Saturday (May 30).
On Friday (May 29), a panel of experts have gathered and have found the need of Taiwan for remdesivir and approved the use of the drug to treat COVID-19 patients in the island, said Wu Shou-mei, Director-General of Taiwan's Food and Drug Administration (FDA), at a daily press briefing.
Wu said, as a preparation for a second wave of infection, Taiwan now is planning to order doses for 1,000 patients, with the order expected to arrive late July.
The director added that the panel experts have discussed that remdesivir can be approved under Taiwan's Article 48-2 of the Pharmaceutical Affairs Act which states that the drug can be manufactured or imported as a "special case."
Remdesivir has a treatment period that can last for not longer than 10 days, with different dosages for people of different weights, Wu said. He added that once the drug is available for use, suppliers are required to implement risk management plan to assure patient safety.
No comments:
Post a Comment